Winnipeg, December 5, 2024 – TheNewswire - Cytophage Technologies Ltd. (‘Cytophage’ or ‘the Company’) (TSXV: CYTO), a leader in bacteriophage research and production, proudly celebrated the grand opening of its new, 20,000-square foot laboratory and manufacturing facility. Designed to support the Company’s continued growth, the facility features cutting-edge laboratories, and a manufacturing suite with proposed GMP (Good Manufacturing Practice) capabilities.  

 

“This new location will dramatically expand our ability to produce bacteriophage solutions at scale, meeting the increasing demand in both human and animal health markets,” said Cytophage CEO Dr. Steven Theriault in his remarks at the grand opening celebration last week. The event was attended by key government officials, industry leaders, and members of the local community, including the Manitoba Minister of Business, Mining, Trade and Job Creation, the Hon. Jamie Moses.  

 

Cytophage CEO Dr. Steven Theriault and Manitoba Minister of Business, Mining, Trade and Job Creation, The Honourable Jamie Moses, at the Ribbon Cutting Ceremony

“Our entire province is so proud of the innovation and creativity in the life sciences sector, and the leading-edge work being done right here in Manitoba,” said Minister Moses in his remarks. “By supporting partnerships like this, we are putting Manitoba on the map as a leader in tackling global healthcare challenges.” 

 

Following a guided tour of the facility, guests participated in a formal program featuring a ribbon-cutting ceremony and a video tribute to the first patient in Canada to receive a phage-based treatment for a prosthetic joint infection.  

 

“Cytophage’s mission is to pioneer innovative solutions to some of the world’s most pressing health challenges,” said Dr. Bradley Cook, Lead Scientist of Cytophage. “With this state-of-the-art facility, we are better equipped than ever to translate groundbreaking research into practical applications that can save lives and improve global health outcomes.” 

 

For more information about Cytophage and its initiatives, please visit the company’s website. 

For photographs from the event, please visit this gallery.  

 

Media Contact: 
Simon Bredin (media@cytophage.com)  

 

For further information please contact:

 

Heather Medwick

Chief Operating Officer

heather@cytophage.com

431 388 8873

Cytophage Investor Alerts: https://cytophage.com/subscribe/

 

About Cytophage Technologies

 

Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

 

Cautionary Statement on Forward-Looking Information

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.